Table 2.
Reference | Year | Setting | LVEF (%) | NYHA class | Proportion of patients with HF of ischaemic aetiology (%) |
---|---|---|---|---|---|
Mavrogeni et al. 13 | 2007 | CHF (LVEF <30%) | 22 ± 6 (levosimendan group); 22 ± 5 (control group) | III–IV | 50 |
Kleber et al. 14 | 2009 | Pulmonary hypertension with signs of right HF in the previous 6 months | Not reported | III–IV | Not available |
Bonios et al. 15 | 2012 | Chronic systolic HF with recent decompensation | 23 ± 7 (levosimendan group); 21 ± 5 (control group) | IV | 50 |
Malfatto et al. 16 | 2012 | CHF (LVEF <35%) requiring at least two hospitalizations in the previous 6 months | 26 ± 5 (levosimendan group); 28 ± 8 (control group) | 3 ± 0.4 (levosimendan group); 3 ± 0.4 (control group) | 72 |
Comin‐Colet et al. 17 | 2015 | CHF (LVEF <35%) with decompensation in the previous 12 months | 25 ± 7 (levosimendan group); 25 ± 6 (control group) | III–IV | 61 |
García‐González et al . 18 | 2016 | CHF with decompensation in the previous 6 months | 25 ± 8 (levosimendan group); 26 ± 10 (control group) | III–IV | Not available |
CHF, chronic heart failure; HF, heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.